Genexine (XKRX:095700) Long-Term Debt : ₩27,126 Mil (As of Dec. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Genexine Long-Term Debt?

Genexine's Long-Term Debt for the quarter that ended in Dec. 2024 was ₩27,126 Mil.

Genexine's quarterly Long-Term Debt increased from Jun. 2024 (₩24,215 Mil) to Sep. 2024 (₩24,766 Mil) and increased from Sep. 2024 (₩24,766 Mil) to Dec. 2024 (₩27,126 Mil).

Genexine's annual Long-Term Debt increased from Dec. 2022 (₩18,484 Mil) to Dec. 2023 (₩22,681 Mil) and increased from Dec. 2023 (₩22,681 Mil) to Dec. 2024 (₩27,126 Mil).

Genexine Long-Term Debt Historical Data

The historical data trend for Genexine's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genexine Long-Term Debt Chart

Genexine Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Long-Term Debt

Get a 7-Day Free Trial

15,775.24

40,649.57

18,483.55

22,681.44

27,125.60

Genexine Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Long-Term Debt	Get a 7-Day Free Trial															22,681.44	22,972.21	24,215.34	24,765.92	27,125.60

Genexine (XKRX:095700) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Genexine Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Genexine's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Genexine Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genexine Inc (XKRX:095700) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

700 Daewangpangyo-ro, Gyeonggi-do, Korea Bio Park Building B, Bundang-gu, Seongnam-si, KOR, 13488

Website

http://www.genexine.com

Genexine Inc is a clinical-stage biotechnology company. It is focused on the development and commercialization of immunotherapeutics and next-generation long-acting biologics. Its primary technologies are Therapeutic DNA vaccine technology and Hyfc platform. The company's product pipeline includes products such as GX-H9, GX-E2, GX-G3, GX-G6, and Papitrol-188 among others.

Genexine Headlines

No Headlines